Artes enters COVID-19 vaccine race
German vaccine developer ARTES Biotechnology GmbH will develop a COVID-19 subunit vaccine based on virus-like particles (VLP), which include two proteins of SARS-CoV-2.
Bayer, Novartis, and Trump convicted by Nature
The politically overhyped use of old malaria drugs in combination with COVID-19-specific candidates has been demonstrated to be dangerous, reports Nature Medicine.
Drug from worms dampens autoimmune response
German researchers have isolated a substance from parasitic roundworm larvae to alleviate inflammation and treat asthma in a rodent model.
COVID-19: Novartis starts study on hyped malaria drug
Up to today, Novartis and Bayer announced donations of several millions of old antimalaria pills based on anecdotical reports of efficacy in COVID-19 patients. Now Novartis has started a study.
COVID 19: Halix ready for vaccine production
Dutch Halix BV will manufacture a ChAdOx1 nCoV-19 vaccine, developed at the University of Oxford .
Carbios SAS publishes PET recycling technology
For years, French Carbios SAS has worked to set up a process that effectively depolymerizes PET, one of the most common plastics. Now its process has been published.
Mobidiags COVID-19 test okayed for emergency use
Researchers reconstruct SARS-CoV-2 evolution
British researchers have tabled a phylogenetic tree showing different subtypes of SARS-CoV-2 developed in Asia, Europe and the US.
COVID-19: Solnatide approved for compassionate use
Austrian COVID-19 patients with severe lung dysfunction for the first time have a treatment option within a compassionate use program for Apeptico’s solnatide.
GE renamed Cytiva upon take-over by Danaher
Following the completion of Danahers 19.5bn take-over of GE Healthcare Life Sciences, GEs CDMO arm is renamed Cytiva.